HC Wainwright & Co. Downgrades Panbela Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Panbela Therapeutics from Buy to Neutral, as per analyst Joseph Pantginis.
May 16, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Panbela Therapeutics from Buy to Neutral, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Neutral by a reputable analyst firm like HC Wainwright & Co. suggests a less favorable view on Panbela Therapeutics' near-term prospects, which could lead to a decline in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100